Astellas Pharma

#News for #investors: Astellas has announced the first quarter of the FY2024 consolidated financial results, ended June 30, 2024. Click on the link below to learn more:  https://lnkd.in/gamM7qNa

We are pleased to announce that Astellas has been named to the #FTSE4Good Index Series for the 13th consecutive year. Based on our achievements in #sustainability and #ESG (Environmental, Social, Governance) practices, we received this recognition from the FTSE Russell, An LSEG Business, a leading global financial index provider. The FTSE4Good Index Series is designed to measure the performance of companies demonstrating strong ESG practices. The FTSE4Good indexes are used by a wide variety of market participants to create and assess responsible investment funds and other products. FTSE Russell evaluations are based on performance in areas such as Corporate Governance, Health & Safety, Anti-Corruption, and Climate Change. Businesses included in the FTSE4Good Index Series meet a variety of environmental, social, and governance criteria. Learn more about our commitment to ESG benchmarks and reporting for investors: https://lnkd.in/gszQnVvr

The 19th term Annual #ShareholdersMeeting was held, and more shareholders attended than last year. We have adopted a hybrid remote attendance-type virtual shareholders meeting.  This type of meeting allows shareholders to exercise their voting rights and ask questions online. This type is an #AdvancedInitiative adopted by few companies out of more than 2,000 listed companies in Tokyo Stock Exchange that hold their annual shareholders meeting in June 2024. The "Notice of Resolution,” "Results of Exercise of Voting Rights,” "Questions and Answers from Shareholders” and “Annual Shareholders Meeting Script” have been published on our corporate website. Click here to learn more:  https://lnkd.in/gEFeZnCt #HybridRemoteAttendanceType #VirtualShareholdersMeeting

We are thrilled to contribute to the second edition of the Good Patient Partnership Guide, inspiring meaningful conversations and progress towards patient-centric practices.  At Astellas, patient centricity is at the core of our global company culture. We take pride in the transformation we have achieved since establishing the Patient Centricity division five years ago, and eagerly anticipate the continued evolution of the industry and regulatory bodies to prioritize patients and caregivers in decision-making.  Join us in creating a truly patient-centric future. Read the latest guide here:   https://lnkd.in/eAEqVRMT

Astellas and Graduate School of Medicine / Faculty of Medicine, Osaka University ("Osaka University") today announced that Astellas Institute for Regenerative Medicine (a wholly owned subsidiary of Astellas), Universal Cells (a wholly owned subsidiary of Astellas) and Osaka University have entered into a research collaboration to develop innovative pluripotent stem cell-derived cartilage organoid cell therapy for the treatment of intervertebral disc degenerative disease. Click on the link below or on the image to learn more:  https://lnkd.in/ggyipRCG #BlindnessAndBeyond #ResearchCollaboration #ResearchAgreement

It was an honor to be with the eye care community at the American Society of Retina Specialists (ASRS) 2024 meeting and connect with those who share our passion for helping patients impacted by vision loss. Thank you to everyone who attended and made ASRS a success! #Ophthalmology #ASRS2024 #EyeHealth

Headed to the American Society of Retina Specialists (ASRS) meeting? Join us at booth 205 to learn more about Astellas’ commitment to advancing innovation in ophthalmology. Our team can’t wait to get to Stockholm and engage with experts who share our mission. #ASRS2024 #EyeHealth #Ophthalmology

El pasado mes de junio hemos estado de celebración: se cumplieron 5 años desde la creación de nuestra división de Patient Centricity, como una función independiente, consolidando nuestro compromiso por ser una compañía verdaderamente centrada en el paciente. Para Astellas, los pacientes están en el centro de todo lo que hacemos, es decir, son nuestra razón de ser. Tanto es así, que nuestro lema es justo ese: PATIENTS ARE WHY.   Pero este compromiso no son solo palabras, sino que se traduce a hechos. Trabajamos incansablemente junto a entidades como Ader Asociación , AEAL, Asociación Española de Afectados por Linfoma, Mieloma y Leucemia, la Alianza General de Pacientes (AGP), Federación Nacional de Asociaciones ALCER, ANCAP. Asociación de Cáncer de Próstata,ASIA - Asociación para la Incontinencia anal, Federación ASEM -Federación Española de Enfermedades Neuromusculares, EUPATI España, Foro Español de Pacientes, FNETH, GEPAC - GRUPO ESPAÑOL DE PACIENTES CON CANCER, Asociación Mácula Retina, Pequeños Superhéroes Asociación, la Asociación Española de Enfermos de Pompe y Plataforma de Organizaciones de Pacientes. A todos vosotros, muchas gracias por dejarnos ser parte de vuestro día a día.   Y, aunque nuestro Mes del Paciente haya finalizado, nuestra acción continúa. Por eso os dejamos con este vídeo en el que hemos preguntado a las asociaciones con las que trabajamos qué les inspira en su trabajo diario.    #AstellasEspaña #PatientCentricity #PATIENTSAREWHY Gaceta Médica

We are thrilled to announce the continued collaboration between Astellas and Patient Advocacy Leaders and Drug Development Industry Network (PALADIN), as well as the launch of the highly anticipated PALADIN Playbook and Resource Repository. This collaboration represents an important milestone in our efforts to advance patient advocacy group (PAG) and industry collaborations, with the ultimate goal of increasing access to life-saving treatments. PALADIN Consortium, in which Astellas is an active participant, plays a pivotal role in establishing more effective relationships between PAGs and biopharmaceutical companies. By developing consensus-based guidelines, training, resources, and competencies, PALADIN aims to optimize collaborations and transform the pace of new medical therapies' development. We are excited about the potential of this collaboration and the impact it will have on relevant stakeholders and the community. Together, we can create meaningful change and drive progress in the industry. Stay tuned for further updates and announcements as we continue this exciting journey with PALADIN. For more information, including PALADIN Playbook and Resource Repository, visit https://lnkd.in/gPk4H8M7. #PatientAdvocacy

Over the past few decades, we’ve seen the gradual improvement in cancer outcomes for patients around the world. As part of this, the emergence of innovation in combination therapies is offering patients with cancer a clinically effective treatment option. However, there are significant challenges that payers, healthcare systems and partners must contend with if we want to ensure timely access to the best care for people affected by cancer. Today marks the launch of a new report ‘A framework for value-aligned pricing of combination therapies,’ commissioned by the Office of Health Economics (OHE) and Astellas. The report calls on the wider healthcare community to turn its attention to a bespoke access model for when a medicine is used in combination. We hope that this will help move us one step closer to a system where patients have access to combination therapies in a fair, timely, and sustainable way. It’s vital that we work together with payers, policymakers and industry leaders. We must act now to ensure we have a reimbursement framework that can enable access to these innovative therapies and move with the times as innovation shifts from singular to multiple treatments. Read the full report at: https://lnkd.in/gFJ-yrdD #Healthcare #Innovation #CombinationTherapy #PatientAccess